Amneal Pharmaceuticals, Inc. reaffirmed earnings guidance for the full year 2021. For the year, the company expects net revenue to be approximately $2.1 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.68 USD | -1.33% | +3.57% | +10.05% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.05% | 2.06B | |
+40.73% | 739B | |
+31.08% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+14.85% | 240B | |
+9.21% | 210B | |
-5.32% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- AMRX Stock
- News Amneal Pharmaceuticals, Inc.
- Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2021